Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05004727 · ClinicalTrials.gov registry record · Phase 4
Multi-Center PAMPA Study
A Phase 4 study of Psoriasis, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 176
- Enrollment target
- 5
- Study locations
NCT05004727 is a Phase 4 study of Psoriasis that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 176 participants, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (64% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT05004727, a Phase 4 study of Psoriasis, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 176 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a multi-center (North-America), randomized, double-blind, placebo-controlled, wait-list, interventional, preventive trial of guselkumab in high-risk psoriasis patients compared to non-biologic standard of care. The primary objective of the proposed trial will be to test the hypothesis that a prolonged, unresolved skin inflammation coupled with musculoskeletal power-doppler ultrasound (MSKPDUS) abnormalities driven by IL-23 increase the risk for transition into PsA and that an intervention that targets one of these pivotal molecules (i.e., Guselkumab) will: 1. Diminish MSKPDUS findings at 24 weeks, and 2. Significantly reduce or prevent the emergence of synovio-enthesial phenotype at year 2.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Guselkumab
Study Locations (5)
New York
- NYU Langone Health - New York
- University of Rochester Medical Center (URMC) - Rochester
Massachusetts
- Brigham and Women's Hospital - Boston
Newfoundland and Labrador
- Memorial University - St. John's
Ontario
- Women's College Research Institute, University of Toronto - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2022-02-16 |
| Est. Completion | 2028-07-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05004727
The ClinicalTrials.gov registry entry for NCT05004727 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (64% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05004727 reports 5 study locations spanning 4 distinct geographic areas - top geographies include New York, Massachusetts, Newfoundland and Labrador.
Frequently Asked Questions
What is clinical trial NCT05004727 about?
NCT05004727 is a clinical study titled "Multi-Center PAMPA Study". This is a multi-center (North-America), randomized, double-blind, placebo-controlled, wait-list, interventional, preventive trial of guselkumab in high-risk psoriasis patients compared to non-biologic standard of care. The primary objective of the proposed trial will be to test the hypothesis that ...
What is the current status of trial NCT05004727?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 176 participants. The study started on 2022-02-16. Estimated completion is 2028-07-31.
What conditions does trial NCT05004727 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT05004727?
The interventions under investigation include: Placebo (DRUG), Guselkumab (DRUG).
Who is sponsoring clinical trial NCT05004727?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05004727 being conducted?
This trial has 5 study locations across Massachusetts, New York, Newfoundland and Labrador, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
RECRUITING · Phase 4
-
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
-
Taltz in Combination With Enstilar for Psoriasis
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.